Keywords: broker, upgrades, zeneca, acquisition, new, product, outlook
Broker Upgrades Zeneca On Acquisition And New Product Outlook
Article | 13 January 1998
UK drugmaker Zeneca underperformed Goldman Sachs' pharmaceutical sectorin 1997 by 7% (underperforming Glaxo Wellcome and SmithKline Beecham by 30%), and now stands at ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
